PBSV · Pharma-Bio Serv, Inc.
4 customers — 19.8% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, revenues from these customers were 19.8%, 16.5%, 12.4% and 5.9%, or a total of 54.6%”
4 customers — 19.8% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, aggregate revenues from these global groups of affiliated companies were 19.8%, 16.5%, 14.2% and 5.9%, or a total of 56.4%”
4 customers — 18.5% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, revenues from these customers were 18.5%, 16.1%, 12.9% and 7.4%, or a total of 54.9%”
4 customers — 18.5% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, aggregate revenues from these global group of affiliated companies were 18.5%, 16.1%, 14.6% and 7.4%”
4 customers — 16.5% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, aggregate revenues from these global groups of affiliated companies were 19.8%, 16.5%, 14.2% and 5.9%, or a total of 56.4%”
4 customers — 16.5% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, revenues from these customers were 19.8%, 16.5%, 12.4% and 5.9%, or a total of 54.6%”
4 customers — 16.1% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, aggregate revenues from these global group of affiliated companies were 18.5%, 16.1%, 14.6% and 7.4%”
4 customers — 16.1% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, revenues from these customers were 18.5%, 16.1%, 12.9% and 7.4%, or a total of 54.9%”
4 customers — 14.6% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, aggregate revenues from these global group of affiliated companies were 18.5%, 16.1%, 14.6% and 7.4%”
4 customers — 14.2% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, aggregate revenues from these global groups of affiliated companies were 19.8%, 16.5%, 14.2% and 5.9%, or a total of 56.4%”
4 customers — 12.9% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, revenues from these customers were 18.5%, 16.1%, 12.9% and 7.4%, or a total of 54.9%”
4 customers — 12.4% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, revenues from these customers were 19.8%, 16.5%, 12.4% and 5.9%, or a total of 54.6%”
4 customers — 7.4% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, aggregate revenues from these global group of affiliated companies were 18.5%, 16.1%, 14.6% and 7.4%”
4 customers — 7.4% of revenue (six months ended April 30, 2026)
“During the six months ended April 30, 2026, revenues from these customers were 18.5%, 16.1%, 12.9% and 7.4%, or a total of 54.9%”
4 customers — 5.9% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, aggregate revenues from these global groups of affiliated companies were 19.8%, 16.5%, 14.2% and 5.9%, or a total of 56.4%”
4 customers — 5.9% of revenue (three months ended April 30, 2026)
“During the three months ended April 30, 2026, revenues from these customers were 19.8%, 16.5%, 12.4% and 5.9%, or a total of 54.6%”
4 customers — 47.1% of receivables (April 30, 2026)
“On April 30, 2026, amounts due from these customers represented 47.1% of the Company’s total accounts receivable balance.”
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBSV
this stock
Pharma-Bio Serv, Inc.
|
$12.37M | -10.0% | -5.3% | — | 0.0% |
|
VEEV
Veeva Systems Inc
|
$44.80B | +23.9% | +28.1% | 45.3 | 3.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.70B | +57.9% | +28.2% | 35.8 | 4.5% |
|
TEM
Tempus AI, Inc.
|
$11.56B | +8.5% | +83.4% | — | 16.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBSV | +28.6% | +10.2% | +5.9% | +28.6% | -10.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +30.5% | +6.9% | -5.3% | +26.5% | -21.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.